Adipose-derived stem cells (ADSCs) can differentiate into various cell types and thus have great potential for regenerative medicine. Herein, rat ADSCs were isolated; transduced with lentiviruses expressing Osterix (Osx), a transcriptional factor essential for osteogenesis. Osx overexpression upregulated key osteogenesis-related genes, such as special AT-rich binding protein 2, alkaline phosphatase, osteocalcin, and osteopontin, at both mRNA and protein levels. In addition, mineral nodule formation and alkaline phosphatase activity were enhanced in Osx-overexpressing ADSCs. The expression of dickkopf-related protein 1, a potent Wnt signaling pathway inhibitor, was also increased, whereas that of β-catenin, an intracellular signal transducer in the Wnt pathway, was decreased. β-catenin expression was partially recovered by treatment with lithium chloride, a canonical Wnt pathway activator. The Osx-expressing ADSCs were then combined with 3D gelatin-coated porous poly(ɛ-caprolactone) scaffolds with a unique release prolife of entrapped recombinant human vascular endothelial growth factor (VEGF). The controlled release of VEGF promoted osteogenic differentiation capacity in vitro. When the scaffold-ADSC complexes were transplanted into rat calvarial critical-sized defects, more bone formed on the gelatin/VEGF-coated scaffolds than on other scaffold types. Taken together, the results indicate that, Osx-overexpression promotes ADSCs' osteogenesis both in vitro and in vivo, which could be enhanced by release of VEGF.
Get full access to this article
View all access options for this article.
References
1.
AlamM.I., AsahinaI., SetoI., OdaM., and EnomotoS.Prefabricated vascularized bone flap: a tissue transformation technique for bone reconstruction. Plast Reconstr Surg, 108, 952, 2001.
2.
LangerR., and VacantiJ.P.Tissue engineering. Science, 260, 920, 1993.
3.
ZukP.A., ZhuM., MizunoH., HuangJ., FutrellJ.W., KatzA.J., et al.Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 7, 211, 2001.
4.
LinC.Y., ChangY.H., LiK.C., LuC.H., SungL.Y., YehC.L., et al.The use of ASCs engineered to express BMP2 or TGF-beta3 within scaffold constructs to promote calvarial bone repair. Biomaterials, 34, 9401, 2013.
5.
ChenQ., YangZ., SunS., HuangH., SunX., WangZ., et al.Adipose-derived stem cells modified genetically in vivo promote reconstruction of bone defects. Cytotherapy, 12, 831, 2010.
6.
LinL., FuX., ZhangX., ChenL.X., ZhangJ.Y., YuC.L., et al.Rat adipose-derived stromal cells expressing BMP4 induce ectopic bone formation in vitro and in vivo. Acta Pharmacol Sin, 27, 1608, 2006.
7.
DengY., ZhouH., ZouD., XieQ., BiX., GuP., et al.The role of miR-31-modified adipose tissue-derived stem cells in repairing rat critical-sized calvarial defects. Biomaterials, 34, 6717, 2013.
8.
LeeJ.S., LeeJ.M., and ImG.I.Electroporation-mediated transfer of Runx2 and Osterix genes to enhance osteogenesis of adipose stem cells. Biomaterials, 32, 760, 2011.
9.
NakashimaK., ZhouX., KunkelG., ZhangZ., DengJ.M., BehringerR.R., et al.The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 108, 17, 2002.
10.
TuQ., ValverdeP., and ChenJ.Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells. Biochem Biophys Res Commun, 341, 1257, 2006.
11.
TuQ., ValverdeP., LiS., ZhangJ., YangP., and ChenJ.Osterix overexpression in mesenchymal stem cells stimulates healing of critical-sized defects in murine calvarial bone. Tissue Eng, 13, 2431, 2007.
12.
ZhangC., ChoK., HuangY., LyonsJ.P., ZhouX., SinhaK., et al.Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci USA, 105, 6936, 2008.
13.
FujitaK., and JanzS.Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer, 6, 71, 2007.
14.
GlassD.A.2nd, BialekP., AhnJ.D., StarbuckM., PatelM.S., CleversH., et al.Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell, 8, 751, 2005.
15.
SinghS., WuB.M., and DunnJ.C.The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials, 32, 2059, 2011.
16.
LinJ., LindseyM.L., ZhuB., AgrawalC.M., and BaileyS.R.Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J Tissue Eng Regen Med, 1, 211, 2007.
17.
KoE., YangK., ShinJ., and ChoS.-W.Polydopamine-assisted osteoinductive peptide immobilization of polymer scaffolds for enhanced bone regeneration by human adipose-derived stem cells. Biomacromolecules, 14, 3202, 2013.
18.
XiaL., LinK., JiangX., FangB., XuY., LiuJ., et al.Effect of nano-structured bioceramic surface on osteogenic differentiation of adipose derived stem cells. Biomaterials, 35, 8514, 2014.
19.
HolzapfelB.M., ReichertJ.C., SchantzJ.T., GbureckU., RackwitzL., NothU., et al.How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev, 65, 581, 2013.
20.
ClarkD., WangX., ChangS., Czajka-JakubowskaA., ClarksonB.H., and LiuJ.VEGF promotes osteogenic differentiation of ASCs on ordered fluorapatite surfaces. J Biomed Mater Res Part A, 103, 639, 2015.
21.
BigalkeC., LudererF., WulfK., StormT., LöblerM., ArbeiterD., et al.VEGF-releasing suture material for enhancement of vascularization: development, in vitro and in vivo study. Acta Biomater, 10, 5081, 2014.
22.
XiaY.P., LiB., HyltonD., DetmarM., YancopoulosG.D., and RudgeJ.S.Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood, 102, 161, 2003.
23.
PoldervaartM.T., GremmelsH., van DeventerK., FledderusJ.O., OnerF.C., VerhaarM.C., et al.Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture. J Control Release, 184, 58, 2014.
24.
GnaviS., di BlasioL., Tonda-TuroC., MancardiA., PrimoL., CiardelliG., et al.Gelatin-based hydrogel for vascular endothelial growth factor release in peripheral nerve tissue engineering. J Tissue Eng Regen Med, 11, 459, 2017.
25.
ChenL., HeZ., ChenB., YangM., ZhaoY., SunW., et al.Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. J Mater Sci Mater Med, 21, 309, 2010.
26.
ZhangQ., TanK., ZhangY., YeZ., TanW.-S., and LangM.In situ controlled release of rhBMP-2 in Gelatin-coated 3D porous poly(ɛ-caprolactone) scaffolds for homogeneous bone tissue formation. Biomacromolecules, 15, 84, 2013.
27.
WangS., MuJ., FanZ., YuY., YanM., LeiG., et al.Insulin-like growth factor 1 can promote the osteogenic differentiation and osteogenesis of stem cells from apical papilla. Stem Cell Res, 8, 346, 2012.
28.
XuB., ZhangJ., BrewerE., TuQ., YuL., TangJ., et al.Osterix enhances BMSC-associated osseointegration of implants. J Dent Res, 88, 1003, 2009.
29.
YeJ.-H., XuY.-J., GaoJ., YanS.-G., ZhaoJ., TuQ., et al.Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs. Biomaterials, 32, 5065, 2011.
30.
CaoZ., LiuR., ZhangH., LiaoH., ZhangY., HintonR.J., et al.Osterix controls cementoblast differentiation through downregulation of Wnt-signaling via enhancing DKK1 expression. Int J Biol Sci, 11, 335, 2015.
31.
KimK.I., ParkS., and ImG.I.Osteogenic differentiation and angiogenesis with cocultured adipose-derived stromal cells and bone marrow stromal cells. Biomaterials, 35, 4792, 2014.
32.
WuW., LeA.V., MendezJ.J., ChangJ., NiklasonL.E., and SteinbacherD.M.Osteogenic performance of donor-matched human adipose and bone marrow mesenchymal cells under dynamic culture. Tissue Eng Part A, 21, 1621, 2015.
33.
ZhangQ., LuoH., ZhangY., ZhouY., YeZ., TanW., et al.Fabrication of three-dimensional poly(epsilon-caprolactone) scaffolds with hierarchical pore structures for tissue engineering. Mater Sci Eng C Mater Biol Appl, 33, 2094, 2013.
34.
TangW., LiY., OsimiriL., and ZhangC.Osteoblast-specific transcription factor Osterix (Osx) is an upstream regulator of Satb2 during bone formation. J Biol Chem, 286, 32995, 2011.
35.
DobrevaG., DambacherJ., and GrosschedlR.SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev, 17, 3048, 2003.
36.
HolyC.E., FialkovJ.A., DaviesJ.E., and ShoichetM.S.Use of a biomimetic strategy to engineer bone. J Biomed Mater Res Part A, 65, 447, 2003.
37.
ReinholtF.P., HultenbyK., OldbergA., and HeinegardD.Osteopontin—a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA, 87, 4473, 1990.
38.
FerraraN., GerberH.P., and LeCouterJ.The biology of VEGF and its receptors. Nat Med, 9, 669, 2003.
39.
YancopoulosG.D., DavisS., GaleN.W., RudgeJ.S., WiegandS.J., and HolashJ.Vascular-specific growth factors and blood vessel formation. Nature, 407, 242, 2000.
40.
GovenderS., CsimmaC., GenantH.K., Valentin-OpranA., AmitY., ArbelR., et al.Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am, 84-A, 2123, 2002.
41.
EtulainJ., NegrottoS., TribulattiM.V., CrociD.O., CarabelliJ., CampetellaO., et al.Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors. PloS One, 9, e96402, 2014.
42.
Suarez-GonzalezD., BarnhartK., MignecoF., FlanaganC., HollisterS.J., and MurphyW.L.Controllable mineral coatings on PCL scaffolds as carriers for growth factor release. Biomaterials, 33, 713, 2012.
43.
YoungS., WongM., TabataY., and MikosA.G.Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release, 109, 256, 2005.
44.
ZhangC., DaiH., and de CrombruggheB.Characterization of Dkk1 gene regulation by the osteoblast-specific transcription factor Osx. Biochem Biophys Res Commun, 420, 782, 2012.
